A Review of Clinical Studies of Bestatin
- 1 January 1980
- book chapter
- Published by Springer Nature
- Vol. 75, 126-132
- https://doi.org/10.1007/978-3-642-81491-4_20
Abstract
Bestatin has no clinical toxicity. It increases the number of T cells and enhances NK cell activity. The optimal dose of bestatin was thought to range from 30–100 mg/day/body, and 200 mg/day/body often decreased T-cell number.Keywords
This publication has 5 references indexed in Scilit:
- EFFECT OF BESTATIN ON NATURAL KILLER ACTIVITYPublished by Elsevier ,1981
- Total synthesis of neomycin C.The Journal of Antibiotics, 1977
- Aminopeptidase activities on the surface of mammalian cellsBiochimica et Biophysica Acta (BBA) - Enzymology, 1976
- Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes.The Journal of Antibiotics, 1976
- Enhancement of delayed-type hypersensitivity by bestatin, an inhibitor of aminopeptidase B and leucine aminopeptidase.The Journal of Antibiotics, 1976